Table 3. Dose reduction, delay for ≥7 days and discontinuation of the chemotherapy and cetuximab components of the regimen.
| Chemotherapy | Cetuximab | |||
|---|---|---|---|---|
| Dose reduction Number of patients (%) |
18 (29.5%) | 3 (5%) | ||
| Maximum dose reduction |
Maximum dose reduction |
Number of patients | Maximum dose reduction |
Number of patients |
| 15% 20% 25% 50% |
2 8 6 2 |
20% | 3 | |
| Dose delay Number of patients (%) |
25 (41%) | 31 (50.8%)a | ||
a
Cetuximab was discontinued permanently in one additional patient due to an allergic infusion reaction